ABSTRACT
INTRODUCTION
Different classes of pathogens trigger specific pattern-recognition receptors (PRRs) differentially expressed on leukocytes 1, 2 . Leukocytes are components of the innate immune system (granulocytes, natural killer cells), the adaptive immune system (T and B lymphocytes), or both (monocytes and dendritic cells). Blood represents both a reservoir and a migration compartment for these cells that might have been exposed to infectious agents, allergens, tumors, transplants or autoimmune reactions. Therefore, blood leukocytes constitute an accessible source of clinically relevant information, and a comprehensive molecular phenotype of these cells can be obtained using gene expression microarrays. This technology has already brought new perspectives in the diagnosis and prognosis of cancer [3] [4] [5] , and the analysis of gene expression signatures in blood leukocytes has led to a better understanding of mechanisms of disease onset and responses to treatment [6] [7] [8] .
Acute infections represent a major cause of morbidity and mortality in the world 9 , especially among children. Concomitantly, our ability to identify infectious agents remains inadequate, particularly if the organism is not present in the blood (or other easily accessible site). These diagnostic obstacles can delay initiation of appropriate therapy which can result in unnecessary morbidity and even death 10 . Furthermore, recent outbreaks caused by emerging pathogens 9, 11 and the increased risk of biothreat foster the need for improved diagnosis of infectious diseases, especially in the acute setting.
We surmised that leukocytes isolated from the peripheral blood of patients with acute infections will carry unique transcriptional signatures which would in turn permit pathogen discrimination. To test this hypothesis, we analyzed gene expression patterns in only.
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Streptococcus pneumoniae, two Gram-positive bacteria; and iv) Escherichia coli, a Gram-negative bacterium.
RESULTS

Patient characteristics
We analyzed PBMCs from 29 patients with E. coli infections, 50 patients with S. aureus infections, 16 patients with S. pneumoniae infections and 36 patients with influenza A infections. We chose young patients because of fewer concomitant diseases and therapies than in older adults. Patients with underlying immunosuppression, receiving immunomodulatory therapy including corticosteroids, or with significant chronic medical problems were excluded. The median (range) duration of hospitalization at the time of blood draw was 3 days (0 -9 days) and the median (range) duration of symptoms was 7 days (1-22 days). The clinical diagnoses included acute respiratory infections, bacteremia, localized abscesses, bone and joint infections, urinary tract infections and meningitis (Table 1) . Patients were treated according to standard hospital protocols and, as such, antimicrobial therapy was promptly initiated in the emergency department.
Step-wise data analysis strategy only.
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To determine whether blood leukocytes isolated from patients with acute infections carry gene expression signatures that allow discrimination between pathogen type, a step-wise analysis was conducted: 1) Statistical group comparison: differentially expressed genes were identified in pair-wise comparisons using non-parametric MannWhitney test. Hierarchical clustering ordered the genes according to their expression levels, revealing reciprocal patterns of expression between the two groups. 2) Sample classification: genes capable of discriminating two groups of patients, i.e. classifiers, were identified through comparison of patient groups of comparable age range and treated with similar classes of antimicrobials (training set). These genes were then evaluated within the same set of patients in a leave-one-out cross-validation scheme. 3) Independent validation of classifier genes: the same genes were tested for their ability to classify an independent group of patients (test set). The patients included in the training sets used to for the identification of the classifier genes were selected very carefully in order to avoid potential confounding factors. After that careful selection, the classifier genes (also described as transcriptional markers) were then evaluated in a new group of patients that was heterogeneous, and therefore more representative of a realistic clinical setting (test set). 4) Independent validation across microarray platforms and chips: the results were then further validated in another set of patients (40 new patients and 6 used in previous analyses) using a different microarray platform (Illumina BeadChip and/or Affymetrix U133plus2 chips). Table 2 About one-third of the patients with bacterial infection displayed elevated expression levels of interferon-related genes. This signature, however, had limited effects on classification outcomes, because samples obtained from patients with bacterial infections lacked the reciprocal expression signature characteristic of influenza infection (under-expressed genes in influenza compared to bacterial infection) and also in part only.
Transcriptional signatures discriminate patients with influenza
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Thus, transcriptional signatures of host response to influenza infection and bacterial infection can be identified. These signatures permit the discrimination between these causative agents.
Transcriptional signatures discriminate patients with E. coli infections from those with
S. aureus infections
To identify genes differentially expressed between patients with E. coli and S. Erythematosus (SLE) demonstrated a "granulopoiesis signature" that was associated with the presence of low-density neutrophils which co-purified with mononuclear cells during density gradient centrifugation 6 . In line with these findings, low-density cells were found in PBMC isolated from 11 randomly selected patients with acute S. aureus infection (data not shown).
Thirty classifier genes which discriminate between the training set of patients with E. coli and S. aureus infections were identified ( Figure 4 and Table 3 and Supplementary Thus, these results demonstrate that blood leukocyte transcriptional signatures distinguish disease etiology in patients with acute infections caused by S. aureus or by E.
coli. Furthermore, notable functional convergence among discriminatory signatures were identified: Interferon-inducible genes were found among genes over-expressed in patient with Influenza A, while genes associated with neutrophils were expressed at higher level in S. aureus compared to E. coli groups.
Classifier genes discriminating samples from patients with acute influenza A, E. coli,
S. aureus or S. pneumoniae infections show minimal overlap
We have defined sets of classifier genes that discriminate patients with influenza A versus bacterial infections, and patients with E. coli versus S. aureus infections. To complete our panel of classifier genes we performed additional pair-wise comparisons and identified sets of genes discriminating patients with S. pneumoniae infections.
Comparison of E. coli (n=11) and S. pneumoniae (n=11) infection groups yielded 264 significantly differentially-expressed genes (P<0.01), and 45 classifier genes patients, were generated using Affymetrix U133A and U133B GeneChips. To take data validation one step further in order to unequivocally confirm our findings, we carried out a similar analysis on additional sets of patients using different microarray platforms.
PBMC expression profiles from a new set of patients were analyzed using the most recent .
Similarly, microarray studies have demonstrated the ability of herpes virus, pseudorabies virus, hepatitis C, varicella-zoster virus or rhinovirus to limit the ability of the host to develop effective anti-viral responses by a variety of mechanisms [37] [38] [39] [40] [41] . Altogether the vast body of in vitro experimental data accumulated over the past years suggests that hosts can mount pathogen-specific transcriptional responses to infections.
Here, we have demonstrated that blood leukocytes gene expression patterns can be used to distinguish patients with acute infections caused by four different pathogens:
influenza A virus; the Gram negative bacterium, E. coli; and Gram-positive bacteria S.
only.
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Two parameters might account for differences in gene expression levels observed in blood leukocytes: 1) changes in transcriptional activity (e.g. up-regulation of interferon-inducible genes) and /or 2) an altered cellular composition of blood samples (e.g. neutrophil signature). Changes in expression due to either one or both of these parameters may be mediated directly by pathogen-derived molecules or the action of secondary factors released by the host (e.g. cytokines). We have not observed major For Our ability to identify etiologic agents responsible for acute infections remains disappointingly low in many clinical situations, and the analysis of blood leukocyte transcriptional profiles has the potential to transform our approach to diagnosis in infectious diseases 42, 43 . Since our goal was to establish the proof of concept, i.e. that blood leukocytes carry signatures that allow discrimination among different microbial pathogens, blood samples were obtained from hospitalized patients with defined infections. Using this approach we were able to establish that leukocytes isolated from the peripheral blood of patients carry transcriptional signatures that can be used to distinguish infectious diseases of different etiologies. Additional studies will be necessary to evaluate the merits of this approach in a relevant clinical setting, i.e. the emergency room. Furthermore, it will be important to determine whether transcriptional analysis of blood leukocytes can provide information that would permit to follow the progression of the disease and assess risks of complications.
In conclusion, this study illustrates the plasticity of immune responses to pathogens in the blood at the transcriptional level, and highlights the potential value of blood leukocytes transcriptional signature analyses as an adjunctive means of diagnosis of infectious diseases.
MATERIALS AND METHODS
Patient Information
Blood samples were obtained from 29 patients with E. coli infections (median age: 2 months; range: 2 weeks -16 years), 50 patients with S. aureus infections (7. 
Processing of Blood Samples
All blood samples were collected in acid citrate dextrose tubes (BD Vacutainer) at CMC, Dallas, TX and immediately delivered at room temperature to the Baylor Institute for Immunology Research, Dallas, TX, for processing. Peripheral blood mononuclear cells (PBMCs) from 3-4 ml of blood were isolated via Ficoll gradient and immediately lysed in RLT reagent (Qiagen, Valencia, CA) with beta-mercaptoethanol (BME) and stored at -80°C (within 4-6 hours from the time of blood draw) in the same laboratory by the same team to standardize the quality and handling of RNA samples.
Microarray assay
Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions and RNA integrity was assessed by using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA).
Affymetrix GeneChips: Double-stranded cDNA was generated from 2-5 micrograms of total RNA, followed by single-round in vitro transcription with biotinlabeled nucleotides, using the Affymetrix RNA transcript labeling kits (Affymetrix Inc, Santa Clara, CA). Biotinylated cRNA targets were purified using the Sample Cleanup Module (Affymetrix), and subsequently hybridized, according to the manufacturer's only.
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Illumina BeadChips: These microarrays consist of 50mer oligonucleotide probes attached to 3µm beads, which are lodged into microwells at the surface of a glass slide.
Samples were processed and data acquired by Illumina Inc. (San Diego, CA). Targets were prepared using the Illumina RNA amplification kit (Ambion, Austin, TX). cRNA targets were hybridized to Sentrix Hu6 BeadChips (>46,000 probes), which were scanned on an Illumina BeadStation 500. Illumina's Beadstudio software was used to assess fluorescent hybridization signals.
Raw data obtained for all 144 microrarray analyses are deposited in the public gene expression database GEO (www.ncbi.nlm.nih.gov/geo/) (accession number GSE6269).
Microarray data analysis
Microarray Suite, Version 5.0 (MAS 5.0; Affymetrix) software was used to assess fluorescent hybridization signals, to normalize signals, and to evaluate signal detection calls. Raw signal intensity values for each probe set were analyzed by algorithms in MAS 5.0. A maximum of eight samples were assigned randomly for hybridization and staining each run day in order to minimize technical variability.
Normalization of signal values per chip was achieved using the MAS 5.0 global method of scaling to the target intensity value of 500 per GeneChip. Analysis was restricted to probe sets for which a P (present) call was obtained in at least 75% of only.
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Nonparametric univariate tests (Mann-Whitney U or Fishers exact test) were used to rank genes on the basis of their ability to discriminate between pre-defined groups of patients.
The ability of the top ranked (i.e. classifier) genes to discriminate the pre-defined class of pathogen was determined by the K-Nearest Neighbors (kNN) method (see Supplementary Method 2 for details) 44 .
only. (Table 1 and Supplementary Table 3 only.
